Clinical Trials Logo

Filter by:
NCT ID: NCT00978887 Completed - Facial Wrinkles Clinical Trials

Retorna Facial Cream in the Treatment of Facial Wrinkles

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy of Retorna facial cream usage in the reduction or total correction of facial wrinkles. The duration of this double-blind placebo controlled phase 3 clinical trial will be 4 weeks. The estimated number of women to be recruited and randomized for the study is 148. Occurrence of adverse effects will also be evaluated.

NCT ID: NCT00978224 Suspended - Clinical trials for Chronic Inflammatory Syndrome

Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether Viusid administration improves malnutrition, atherosclerosis, erythropoietin response and the frequency of infection episodes in subjects with Chronic Inflammatory Syndrome under hemodialysis treatment. The duration of this double-blind placebo controlled phase 3 clinical trial will be 60 weeks. All patients enrolled in the study will be receiving the standard treatment for Chronic Inflammatory Syndrome including hemodialysis and administration of a hypercaloric and hyperproteic diet. Efficacy assessment will be carried out 12 weeks after the end of Viusid or placebo treatment.

NCT ID: NCT00975117 Completed - Male Infertility Clinical Trials

Spermotrend in the Treatment of Male Infertility

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the administration of the dietary supplement Spermotrend improves spermatogenesis parameters in subjects with male infertility unrelated to major testicular conditions. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of males with infertility to be recruited and randomized for the study is 86.

NCT ID: NCT00969527 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy of Oncoxin+Viusid administration in the treatment of rheumatoid arthritis. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons with rheumatoid arthritis to be recruited and randomized for the study is 86. The primary outcome measure: DAS28 score will be assessed at the end of the study.

NCT ID: NCT00967681 Completed - Clinical trials for Breast Fibrocystic Disease

Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.

NCT ID: NCT00959491 Active, not recruiting - Colonoscopy Clinical Trials

A Prospective Study of a New Immunological Fecal Occult Blood Test

RLHV
Start date: October 2009
Phase: N/A
Study type: Observational

The purpose of the investigators study is to evaluate the diagnostic ability of a new immunological fecal occult blood test in Cuban patients undergoing colonoscopy .

NCT ID: NCT00957086 Active, not recruiting - Clinical trials for Carcinoma, Squamous Cell of Head and Neck

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Start date: August 13, 2009
Phase: Phase 3
Study type: Interventional

The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection of their locally advanced HNSCC will confer therapeutic advantage.

NCT ID: NCT00886873 Completed - Uterine Fibroids Clinical Trials

Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids

Mifemyo_2
Start date: May 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of this study are to estimate the efficacy and safety of the daily administration for 6 months of 5 mg versus 10 mg. A 6 month follow-up of subjects is carried out to estimate how the effects of mifepristone are kept in time. The hypothesis of this study is that both mifepristone doses reduce the volume of the myoma up to 50% in six months treatment.

NCT ID: NCT00872482 Terminated - Clinical trials for Metastatic Non-Small Cell Lung Cancer

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Start date: April 2009
Phase: Phase 2
Study type: Interventional

This is a randomized, Phase II study designed to investigate Nimotuzumab plus whole-brain radiation therapy (WBRT)and to compare it rith WBRT alone in patients with brain metastases from non-small cell lung cancer (NSCLC). The purpose of the study is to assess the efficacy of nimotuzumab in combination with WBRT.

NCT ID: NCT00820651 Completed - Insulin Resistance Clinical Trials

Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether the addition of Diamel, a nutritional supplement, to hypocaloric diet and exercise could improve the histological results (steatosis, necro-inflammatory activity and fibrosis), insulin resistance, aminotransferase levels and anthropometric measures in comparison with a placebo-controlled group with hypocaloric diet and exercise during 52 weeks of treatment in patients with nonalcoholic steatohepatitis.